바이오인

2023 글로벌 제약·바이오 R&D 동향

Oncology

◈ 목차

I. Biopharma Dealmaking in 2022

I-I. M&A, Partnership

I-II. Top 10 M&As

I-III. Top 10 Partnership

II. Oncology Trends in 2022

II-I. Oncology spending(2026), R&D(2022)

II-II. 2023 Valuable clinical trials

II-III. 2022 Approvals(FDA, EMA)

II-IV. Modality

III. IO, BsAb, CGT, ADC in Oncology 2022

III-I. IO(R&D 2021, 2022)

III-II. BsAb(R&D 2022, Current deals)

III-III. Cell, Gene therapy(R&D 2022)

III-IV. ADC(R&D 2022)

IV. ADC in Oncology

IV-I. FDA approval

IV-II. ADC(R&D 2022)

IV-III. Current Top 14 Deals(2022~2023.05.)

IV-IV. Major modality in current Dealmaking

IV-V. Ongoing clinical trials

V. Learning & Key Takeaways

◈본문

I-I. Overall current deals

Retrieved from Nat Rev Drug Disc(2023)

Retrieved from Nat Rev Drug Disc(2022)

❖ Dealmaking

- M&As & Partnerships(2021, 2022)

❖ Breakdown by TA

...................(계속)

☞ 자세한 내용은 내용바로가기 또는 첨부파일을 이용하시기 바랍니다.